DOCSLIB.ORG

Metabolomics2010 Metabolomics2010 27 JUNE – 1 JULY, 2010 AMSTERDAM RAI the NETHERLANDS

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

METABOLOMICS2010 METABOLOMICS2010 27 JUNE – 1 JULY, 2010 AMSTERDAM RAI THE NETHERLANDS Breakthroughs in plant, microbial and human biology, clinical and nutritional research, and biomarker discovery PLANT METABOLOMICS PLATFORM WWW.METABOLOMICS2010.COM SCHEDULE AT GLANCE Time slot Sunday 27th June Monday 28th June Tuesday 29th June Wednesday 30th June Thursday 1st July Plenary session Plenary session Plenary session Plenary session Nutrition & Health Sponsored by 09.00 - 10.30 Applications Galore! Advanced Technologies Young Scientists Unilever co-organized with NUGO Workshops Sponsored by MPF Metabolomics-assisted breeding 10.00 - 12.30 Coffee Coffee Coffee Coffee Coffee 10.30 -11.00 10.30 -11.00 10.30 -11.00 10.30 -11.00 10.30 -11.00 Parallel Session 1A Mass Model systems for Databases, Bioinformatics Genome, metabolome and Plenary session 11.00 - 12.30 Spectrometry translational research & data analysis microbiome The future Parallel Session 1B NMR Technology Updates Biotic interactions and plant Society issues 11.00 - 12.30 stress Awards Metabolomics2011 Lunch & Posters Lunch & Posters Lunch & Posters& Lunch & Posters& Lunch & Posters& Lunch & departure 12.30 - 14.00 Sponsor Workshops Sponsor Workshops Sponsor Workshops Parallel session Metabolomics and Biomarker Pharmacometabolomics, Pathways discovery and NuGO Workshop (invitees only) 14.00 - 15.30 discovery personalized medicine & disease pathophysiology future of health system Workshops 14.00 - 16.30 Parallel Session Environment and Ecology Developments in plant Plant Systems biology 14.00 - 15.30 metabolomics 2A Biostatistics Tea Chemometrics & Tea Tea Tea 15.30 – 16.00 Bioinformatics 15.30 – 16.00 15.30 – 16.00 15.30 – 16.00 Parallel Session Drug discovery & drug Systems biology of Hot Topics 16.00 - 17.30 development mammalian/microbial metabolism 2B Plant Metabolomics Parallel Session Plant Physiology Volatiles & secondary Food & Applied 16.00 - 17.30 metabolism metabolomics Early evening Opening Ceremony Posters + wine Posters + wine activity 17.30 17.30 – 18.45 17.30 - 19.00 17.30 - 19.00 Kick-off Plenary Prof. LEROY HOOD Reception 18.45 - 20.00 Workshops 18.30 - 19.45 Workshops 18.30 - 19.45 Conference Dinner Okura Hotel 19.30 SCHEDULE AT GLANCE.indd 1 11-06-2010 11:32:22 EU-020A4.ps T:\MISC\ADS\EU-020\EU-020A4.cdr Monday, June 07, 2010 4:41:42 PM Color profile: Disabled 8667-Metabolomic-210x297-June2010_New Advert Temp 01/06/2010 15:53 Page 1 . d e v r e s e r s t h g i r l l A . c n I c i f i t n e i c S r e h s i F o m r e h T 0 1 0 2 © Metabolomic profiling & identification – with comprehensive characterization • Exactive high-performance LC-MS for accurate, precise profiling • Qualitative and quantitative results in the same analysis • SIEVE software - detection and quantification of low-level metabolites • Identification of biologically significant targets for further research • LTQ Orbitrap for superior sensitivity, resolution, mass accuracy. Thermo Scientific Exactive • Confident elemental composition determination • Mass Frontier for compound structural elucidation. • Ultimate performance for comprehensive metabolome analysis. Come and visit us on Booth 8 at Metabolomics 2010 in Amsterdam. Moving science forward Unilever's vision is to work to create a better future every day. We help people feel good, look good and get more out of life with brands and services that are good for them and good for others. We will inspire people to take small everyday actions that can add up to a big difference for the world. We will develop new ways of doing business that will allow us to double the size of our company while reducing our environmental impact. Today Unilever employs 163,000 people in 100 countries worldwide, and supports the jobs of many thousands of distributors, contractors and suppliers. With 400 brands spanning 14 categories of home, personal care and foods products, no other company touches so many people's lives in so many different ways. We invest nearly €1 billion every year in cutting-edge research and development, and have six strategic R&D laboratories around the world that explore new thinking and techniques to help develop our products. We particularly value our interactions with experts from academia, health authorities, governments and non-governmental organisations and look forward to at the Metabolomics Society Meeting 2010 in Amsterdam. www.unilever.com [ INTRODUCING XEVO G2 QTof ] Your qualitative and quantitative questions answered. [ Comprehensively. ] The Xevo™ G2 QTof from Waters. Our next-generation exact mass MS/MS benchtop system maintains the integrated workflow benefits of Engineered Simplicity™ found in our existing Xevo QTof, while also incorporating the groundbreaking QuanTof™ technology of our SYNAPT™ G2 system. So whether you’re focused on qualitative or quantitative goals, you’ll make better decisions faster and easier than ever before. Learn more at waters.com/xevog2 ©2010 Waters Corporation. Waters, Xevo, Synapt, QuanTof, Engineered Simplicity and The Science of What's Possible are trademarks of Waters Corporation. [ INTRODUCING XEVO G2 QTof ] Your qualitative and quantitative questions answered. [ Comprehensively. ] The Xevo™ G2 QTof from Waters. Our next-generation exact mass MS/MS benchtop system maintains the integrated workflow benefits of Engineered Simplicity™ found in our existing Xevo QTof, while also incorporating the groundbreaking QuanTof™ technology of our SYNAPT™ G2 system. So whether you’re focused on qualitative or quantitative goals, you’ll make better decisions faster and easier than ever before. Learn more at waters.com/xevog2 ©2010 Waters Corporation. Waters, Xevo, Synapt, QuanTof, Engineered Simplicity and The Science of What's Possible are trademarks of Waters Corporation. Dionex Welcomes You to Metabolomics 2010 Amsterdam hosts this year’s Metabolomics 2010 conference from June 27th to July 1st. Dionex will present its new ICS-5000 system, the world’s first capillary IC system, the UltiMate® 3000 RSLCnano UHPLC system, and the CoulArray® Multi-Channel Electrochemical detector. Visit us to learn more about analytical solutions based on the following platforms: • ICS-5000 Capillary Ion Chromatograph System, the world’s first capillary Reagent-Free™ Ion Chromatography (RFIC™) system. Developed with flexibility, modularity, and ease-of-use in mind, the ICS-5000 combines the highest sensitivity with convenience. With the ability to analyze samples at capillary, microbore, or standard flow rates (or any combination of two, in a dual system) the system is simply Always Ready. • CoulArray Multi-Channel Electrochemical Detector produces qualitative information for compound identification, resolves coeluting peaks, determines peak purity, simplifies sample preperation, and measures multiple analytes per sample. • UltiMate 3000 RSLCnano UHPLC Systems represent the future of nano LC/MS: more peaks, better information, and faster discovery. These systems have been designed to optimize low flow separations and facilitate easy coupling to mass spectrometry to provide the best resolution, sensitivity, and selectivity for nano LC and proteomics applications. Visit Dionex at Metabolomics 2010 or find more information on www.dionex.com. UltiMate 3000 RSLCnano system UltiMate 3000 system and CoulArray® detector ICS-5000 Capillary IC system Reagent-Free and RFIC are trademarks, UltiMate, and CoulArray are registered trademarks of Dionex Corporation. We're all different. So are you. the right medicine in the right place at the right time The future of Diagnostics follows a new plan: Tailored biomarkers for health. www.biocrates.com Bruker Biospin Bruker Daltonics Metabolic Profiler The world‘s only fully Integrated Solution for Metabolic Profiling in Systems Biology Drug Discovery & Development Clinical Research/Public Health Studies Plant Science Nutrition & Food Microbial Research For research use only. Not for use in diagnostic procedures. www.bdal.com/metabolicprofiler Unique Combination of NMR & LC-MS Flexible software tools for statistical analysis Sophisticated data management with SampleTrack Spectral libraries for NMR & MS data On-line sample preparation Unique de-novo structure elucidation capability Confident formula finding with SmartFormula 3D Fully synchronized or independent operation think forward NMR / LC-MS Metabolic-Profiler_210x148.5.indd 1 04.05.2010 16:07:54 Uhr Shimadzu_Biotechniques 28.09.2007 12:00 Uhr Seite 1 Bionavigate. Metabolic Pathways Sigma-Aldrich® metabolite standards, enzymes, HPLC solvents, and separation technologies help you navigate the metabolic pathways to biomarker discovery. • Unique isolated and synthetic metabolites • Unique stable-isotope-labelled metabolites • Biomarker metabolites • Metabolic enzymes, substrates and inhibitors • Amino acid, carbohydrate, and lipid metabolite libraries To view our comprehensive metabolomic resources, reagents and kits, visit sigma.com/metabolomics Sigma and Sigma-Aldrich are registered trademarks belonging to Sigma-Aldrich Co. and its affi liate Sigma-Aldrich Biotechnology, L.P. 30 years Metabolomics at TNO for Food and Pharma Metabolomics at TNO Innovations in technology • Innovative analytics • Data extraction • Multivariate statistics • Bioinformatics • Biological interpretation Innovations in applications • Nutrition and health • Microbial and food production • Metabolic syndrome • Toxicity and safety www.tno.nl/Pharma www.tno.nl/Food 10-3663 TNO adv 1-2 A4 Bioavailability-05.indd 1 10-06-10 18:11 Dedicated to supporting life
Recommended publications
  • Small Molecule–Mediated Reprogramming of the Epithelial–Mesenchymal Transition

    Small Molecule–Mediated Reprogramming of the Epithelial–Mesenchymal Transition

    bioRxiv preprint doi: https://doi.org/10.1101/106591; this version posted February 16, 2017. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Small molecule–mediated reprogramming of the epithelial–mesenchymal transition prevents fibrosis Running title: Reversion of fibrosis by chromones Han-Soo Kim,1,2* Jun-Hwan Kim,1,3* Ji Yong Lee,2 Young-Min Yoon,3 Ik-Hwan Kim,4 Ho- Sup Yoon5 and Byung-Soo Youn3# 1Institute for BioMedical Convergence, Catholic Kwandong University-International St. Mary’s Hospital, Incheon 22711, Republic of Korea , 2Department of Biomedical Sciences, Catholic Kwandong University College of Medicine, Gangneung-si, Gangwon-do 25601, Republic of Korea. 3#705 Ace High-end Tower 9th 233,Gasandigital-1-ro, Geumcheon- gu, Seoul, 08501, Republic of Korea, 4Department of Biotechnology, Korea University. Seoul 02841and 5Department of Genetic Engineering, College of Life Sciences, Kyung Hee University, Yongin-si, Gyeonggi-do 446-701, Republic of Korea and 5School of Biological Sciences, Nanyang Technological University, 60 Nanyang Drive, 637551, Singapore *These contributes equally to this work. #Corresponding author: Byung-Soo Youn, PhD, OsteoNeuroGen, Inc. Ace High-end Tower 9th 233, Gasandigital-1-ro, Geumcheon-gu, Seoul, 08501, Republic of Korea Email: [email protected], Tel) 822- 6267 2737 Fax) 822-6267-2740 １ bioRxiv preprint doi: https://doi.org/10.1101/106591; this version posted February 16, 2017. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.
  • We Wish to Share That with You By

    We Wish to Share That with You By

    T HE DEPARTMENT OF BIOENGINEERING The UCSD Bioengineering Program was initiated in 1966 by Drs. Y.C. Fung, Marcos Intaglietta, and Benjamin Zweifach within the Department of Aeronautical Mechanics and Engineering Science. In August 1994 the UC Office of the President approved our request to form a Department of Bioengineering, the first in the UC System. It is wonderful that our Department is celebrating the tenth anniversary of its establishment. While an age of 10 years is young, we had a gestation period of 28 years, which are covered in this book together with the last 10 years. At this momentous occasion, I wish to express my sincere thanks to all my colleagues: faculty, research scientists, staff and students, for their wonderful work as a team in making the Department such a marvelous place to be, both scientifically and interpersonally. On behalf of the Department, I also wish to take this opportunity to thank the generous support and strong encouragement by our friends everywhere in the country and our administration at UCSD and the UC system. Our friends and colleagues are extremely precious, much more than the diamond on the cover of this book*, which is a symbol that represents the tenth anniversary. Sincerely, Shu Chien Chair, Department of Bioengineering NNIVERSARY A * The preparations for this book and the celebration on August 14, 2004, have been made TH possible by the outstanding work by the following members of UCSD central administration, Jacobs School External Relations Office, and Department of Bioengineering (listed alphabetically): 10 Kelly Briggs, Suzie Dandos, Chandra Ewell. Jennifer Griffin, Denine Hagen, Irene Jacobo, Paul Laperruque, Beth Maples, Carolyn Post-Ladd, Jeff Sanchez, and Loretta Smith.
  • Supplementary Materials Evodiamine Inhibits Both Stem Cell and Non-Stem

    Supplementary Materials Evodiamine Inhibits Both Stem Cell and Non-Stem

    Supplementary materials Evodiamine inhibits both stem cell and non-stem-cell populations in human cancer cells by targeting heat shock protein 70 Seung Yeob Hyun, Huong Thuy Le, Hye-Young Min, Honglan Pei, Yijae Lim, Injae Song, Yen T. K. Nguyen, Suckchang Hong, Byung Woo Han, Ho-Young Lee - 1 - Table S1. Short tandem repeat (STR) DNA profiles for human cancer cell lines used in this study. MDA-MB-231 Marker H1299 H460 A549 HCT116 (MDA231) Amelogenin XX XY XY XX XX D8S1179 10, 13 12 13, 14 10, 14, 15 13 D21S11 32.2 30 29 29, 30 30, 33.2 D7S820 10 9, 12 8, 11 11, 12 8 CSF1PO 12 11, 12 10, 12 7, 10 12, 13 D3S1358 17 15, 18 16 12, 16, 17 16 TH01 6, 9.3 9.3 8, 9.3 8, 9 7, 9.3 D13S317 12 13 11 10, 12 13 D16S539 12, 13 9 11, 12 11, 13 12 D2S1338 23, 24 17, 25 24 16 21 D19S433 14 14 13 11, 12 11, 14 vWA 16, 18 17 14 17, 22 15 TPOX 8 8 8, 11 8, 9 8, 9 D18S51 16 13, 15 14, 17 15, 17 11, 16 D5S818 11 9, 10 11 10, 11 12 FGA 20 21, 23 23 18, 23 22, 23 - 2 - Table S2. Antibodies used in this study. Catalogue Target Vendor Clone Dilution ratio Application1) Number 1:1000 (WB) ADI-SPA- 1:50 (IHC) HSP70 Enzo C92F3A-5 WB, IHC, IF, IP 810-F 1:50 (IF) 1 :1000 (IP) ADI-SPA- HSP90 Enzo 9D2 1:1000 WB 840-F 1:1000 (WB) Oct4 Abcam ab19857 WB, IF 1:100 (IF) Nanog Cell Signaling 4903S D73G4 1:1000 WB Sox2 Abcam ab97959 1:1000 WB ADI-SRA- Hop Enzo DS14F5 1:1000 WB 1500-F HIF-1α BD 610958 54/HIF-1α 1:1000 WB pAkt (S473) Cell Signaling 4060S D9E 1:1000 WB Akt Cell Signaling 9272S 1:1000 WB pMEK Cell Signaling 9121S 1:1000 WB (S217/221) MEK Cell Signaling 9122S 1:1000
  • Graphical Abstract CG 18-1-MS

    Graphical Abstract CG 18-1-MS

    Send Orders for Reprints to [email protected] 3 Current Genomics, 2017, 18, 3-26 REVIEW ARTICLE ISSN: 1389-2029 eISSN: 1875-5488 Impact Factor: 2.43 Established Human Cell Lines as Models to Study Anti-leukemic Effects of Flavonoids BENTHAM SCIENCE Katrin Sak* and Hele Everaus Department of Hematology and Oncology, University of Tartu, Tartu, Estonia Abstract: Despite the extensive work on pathological mechanisms and some recent advances in the treatment of different hematological malignancies, leukemia continues to present a significant challenge being frequently considered as incurable disease. Therefore, the development of novel therapeutic agents with high efficacy and low toxicity is urgently needed to improve the overall survival rate of pa- A R T I C L E H I S T O R Y tients. In this comprehensive review article, the current knowledge about the anticancer activities of Received: May 11, 2015 flavonoids as plant secondary polyphenolic metabolites in the most commonly used human established Revised: November 20, 2015 Accepted: November 27, 2015 leukemia cell lines (HL-60, NB4, KG1a, U937, THP-1, K562, Jurkat, CCRF- CEM, MOLT-3, and MOLT-4) is compiled, revealing clear anti-proliferative, pro-apoptotic, cell cycle arresting, and differ- DOI: 10.2174/138920291766616080316 entiation inducing effects for certain compounds. Considering the low toxicity of these substances in 5447 normal blood cells, the presented data show a great potential of flavonoids to be developed into novel anti-leukemia agents applicable also in the malignant cells resistant to the current conventional che- motherapeutic drugs. Keywords: Antiproliferation, Apoptosis, Cell cycle arrest, Cytotoxicity, Differentiation, Flavonoids, Leukemia, Human cell lines.
  • Shilin Yang Doctor of Philosophy

    Shilin Yang Doctor of Philosophy

    PHYTOCHEMICAL STUDIES OF ARTEMISIA ANNUA L. THESIS Presented by SHILIN YANG For the Degree of DOCTOR OF PHILOSOPHY of the UNIVERSITY OF LONDON DEPARTMENT OF PHARMACOGNOSY THE SCHOOL OF PHARMACY THE UNIVERSITY OF LONDON BRUNSWICK SQUARE, LONDON WC1N 1AX ProQuest Number: U063742 All rights reserved INFORMATION TO ALL USERS The quality of this reproduction is dependent upon the quality of the copy submitted. In the unlikely event that the author did not send a com plete manuscript and there are missing pages, these will be noted. Also, if material had to be removed, a note will indicate the deletion. uest ProQuest U063742 Published by ProQuest LLC(2017). Copyright of the Dissertation is held by the Author. All rights reserved. This work is protected against unauthorized copying under Title 17, United States C ode Microform Edition © ProQuest LLC. ProQuest LLC. 789 East Eisenhower Parkway P.O. Box 1346 Ann Arbor, Ml 48106- 1346 ACKNOWLEDGEMENT I wish to express my sincere gratitude to Professor J.D. Phillipson and Dr. M.J.O’Neill for their supervision throughout the course of studies. I would especially like to thank Dr. M.F.Roberts for her great help. I like to thank Dr. K.C.S.C.Liu and B.C.Homeyer for their great help. My sincere thanks to Mrs.J.B.Hallsworth for her help. I am very grateful to the staff of the MS Spectroscopy Unit and NMR Unit of the School of Pharmacy, and the staff of the NMR Unit, King’s College, University of London, for running the MS and NMR spectra.
  • One Design Racing

    One Design Racing

    DRAGON ] ONE DESIGN RACING 2017 REVIEW • 2018 PREVIEW IIDADA YYearbookearbook 2017.indd2017.indd 1 115/01/20185/01/2018 111:241:24 Contents IDA Offi cers & Offi cials 4 Message from The Chairman President IDA Sailing Co-ordinator Why is everyone is talking 7 Current Champions H.M. King Constantine Martin Payne (GBR) Mob +44 7788 587017 8 Extra, Extra, Read All About It Vice Presidents E: [email protected] 11 Introducing the Dragon Silver Cup H.R.H. Prince Henrik of Denmark about the new 12 Dave Dellenbaugh – Considering Current Frederik , Crown Prince of Denmark IDA Technical Committee 18 Poul Richard Hoj-Jensen - Half a century with the Dragons Christopher Dicker 20 Mike Hayles – Sailing Naiad with my wife and friends Poul Richard Hoj-Jensen Chairman Klaus Diederichs (GBR) Petticrow’s V6 Dragon? 22 Rogues Gallery Chairman E: [email protected] 24 Yves Leglise – The rules of starting and fi nishing Vasily Senatorov (RUS) 26 IDA Honours Dedicated Members E: [email protected] Members Everyone wants to know about Upgraded rig controls and a review of our systems 26 Fresh blood for the Dragons Gunter Ahlers (GER) Chief Measurer the new v6 Dragon as it offers enable comfortable and highly efficient crew work. 35 Interport 2017 Vice Chairmen E: [email protected] sailors our most advanced and 36 National Classes focus on Portugal Stéphane Baseden (FRA) Graham Bailey (GBR) E: [email protected] E: [email protected] The new v6 38 National Classes focus on Ireland refined Dragon yet. Helmut Schmidt (GER) Ron James (GBR)
  • Agriculture in an Urbanizing Society Volume Two

    Agriculture in an Urbanizing Society Volume Two

    Agriculture in an Urbanizing Society Volume Two Agriculture in an Urbanizing Society Volume Two: Proceedings of the Sixth AESOP Conference on Sustainable Food Planning Edited by Rob Roggema Agriculture in an Urbanizing Society Volume Two: Proceedings of the Sixth AESOP Conference on Sustainable Food Planning Edited by Rob Roggema This book first published 2017 Cambridge Scholars Publishing Lady Stephenson Library, Newcastle upon Tyne, NE6 2PA, UK British Library Cataloguing in Publication Data A catalogue record for this book is available from the British Library Copyright © 2017 by Rob Roggema and contributors All rights for this book reserved. No part of this book may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without the prior permission of the copyright owner. ISBN (10): 1-4438-9984-4 ISBN (13): 978-1-4438-9984-0 TABLE OF CONTENTS Volume One List of Illustrations ..................................................................................... ix List of Tables ............................................................................................ xix Preface ...................................................................................................... xxi Introduction ................................................................................................. 1 PART I: Spatial Design Chapter One ................................................................................................. 7 Planning
  • Study on Structure Activity Relationship of Natural Flavonoids Against Thrombin by Molecular Docking Virtual Screening Combined with Activity Evaluation in Vitro

    Study on Structure Activity Relationship of Natural Flavonoids Against Thrombin by Molecular Docking Virtual Screening Combined with Activity Evaluation in Vitro

    molecules Article Study on Structure Activity Relationship of Natural Flavonoids against Thrombin by Molecular Docking Virtual Screening Combined with Activity Evaluation In Vitro 1,2, 3,4, 3,4 1 1,2 Xiaoyan Wang y, Zhen Yang y, Feifei Su , Jin Li , Evans Owusu Boadi , Yan-xu Chang 1,2,* and Hui Wang 3,4,* 1 Tianjin State Key Laboratory of Modern Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin 300193, China 2 Tianjin Key Laboratory of Phytochemistry and Pharmaceutical Analysis, Tianjin University of Traditional Chinese Medicine, Tianjin 300193, China 3 Tianjin Key Laboratory of Chinese Medicine Pharmacology, Tianjin University of Traditional Chinese Medicine, Tianjin 300193, China 4 College of Chinese Materia Medica, Tianjin University of Traditional Chinese Medicine, Tianjin 300193, China * Correspondence: [email protected] (Y.-x.C.); [email protected] (H.W.); Tel./Fax: +86-22-59596163 (Y.-x.C.) These authors contributed equally to this work. y Received: 20 December 2019; Accepted: 18 January 2020; Published: 20 January 2020 Abstract: Thrombin, a key enzyme of the serine protease superfamily, plays an integral role in the blood coagulation cascade and thrombotic diseases. In view of this, it is worthwhile to establish a method to screen thrombin inhibitors (such as natural flavonoid-type inhibitors) as well as investigate their structure activity relationships. Virtual screening using molecular docking technique was used to screen 103 flavonoids. Out of this number, 42 target compounds were selected, and their inhibitory effects on thrombin assayed by chromogenic substrate method. The results indicated that the carbon-carbon double bond group at the C2, C3 sites and the carbonyl group at the C4 sites of flavones were essential for thrombin inhibition, whereas the methoxy and O-glycosyl groups reduced thrombin inhibition.
  • Investment Committee Paper Agenda

    Investment Committee Paper Agenda

    NOVA SCHOOL OF BUSINESS AND ECONOMICS Master in Finance / Management PRIVATE EQUITY CHALLENGE Professors: Luís Mota Duarte Fábio Santos Carolina Lopes Mathieu Bourque Pedro Pinto Coelho Pedro Mendes 30394 / 4108 29792 / 3980 20220 / 3898 20740 / 3737 INVESTMENT COMMITTEE PAPER AGENDA 4 Executive Summary 31 Business Plan & Forecasts Business Plan Revenues 5 Company Overview Operating Income CAE Profile Cashflow Business Model Competitive Positioning 36 Capital Structure Valuation 10 Market Overview Leverage Market Overview Simulation & Training Overview Sources and Uses Civil Aviation Market LBO Returns Defence & Security Market Healthcare Market Competitive Landscape 41 Exit & Due Diligence Exit Overview Trade Sale 16 Historical Financial Analysis Initial Public Offering Income Statement Due Diligence Balance Sheet Cashflow 46 Appendix 21 Investment Thesis Deal Rationale and Strategy Value creation PE CHALLENGE | CAE, INC. 3 INVESTMENT COMMITTEE PAPER EXECUTIVE SUMMARY ENTRY VALUE CREATION EXIT ▪ CAE Inc. is a simulation and training company that operates CAE’s value creation plan consists of a Buy & Build strategy ▪ The most suitable exit strategy is a carve-out of the across three segments – Civil Aviation, Defence & Security allied with portfolio expansion and operational improvements Healthcare branch while pursuing a sale of the other two and Healthcare segments to a strategic partner ▪ Based in Canada, CAE currently has operations worldwide in ▪ With tremendous demand for pilots from airlines over the ▪ The HC segment is most likely to list in the Nasdaq stock over 35 countries and has been a consistent dominant next couple of decades, supply is expected to follow such exchange. Civil aviation and Defence & Security can be player in its industry (with 51% and 19% market share in trend.
  • Ruling Family, Leading Figures Urged to Stay Away from Polls

    Ruling Family, Leading Figures Urged to Stay Away from Polls

    SUBSCRIPTION TUESDAY, NOVEMBER 8, 2016 SAFAR 8, 1438 AH www.kuwaittimes.net Legislations May lays Delhi shuts Veteran needed to groundwork schools as smog Evra called address key for post-Brexit sparks health up to France issues: 3Sour India21 trade deal ‘emergency’28 squad19 Ruling family, leading figures Min 27º urged to stay away from polls Max 16º High Tide 03:58 & 18:36 Reform initiative also calls for change in voting system Low Tide 11:11 & 23:25 40 PAGES NO: 17044 150 FILS KUWAIT: A group of leading personalities that include for- mer ministers and lawmakers, calling itself the Reform and Clinton, Trump in frenzied campaign finale National Consensus Initiative Group, yesterday launched a political reconciliation initiative to end the deterioration in the country’s affairs. The initiative called on “competing members of the ruling family and other leading figures” to stop interfering in the election through “political money” and other means that could influence the outcome of the parliamentary polls, allowing them to ensure the success of their “candidates” in the election. The initiative did not provide further details, but there have been increasing accusations that some influential fig- ures, in a bid to influence the outcome of the polls to serve their interests, have pumped millions of dinars into the process. Allegations of vote-buying and other forms of bribery and corruption have been repeatedly made, but very few people have been sent to court over such claims. The group consists of 20 personalities representing vari- ous political schools of thought and includes people like for- mer justice minister and deputy speaker Meshari Al-Anjari, veteran politician and former minister Yousef Al-Nasef, for- mer minister and MP Abdulwahab Al-Haroun, former minis- ter Abdulwahab Al-Wazzan and several other dignitaries.
  • Study on Structure Activity Relationship of Natural Flavonoids

    Study on Structure Activity Relationship of Natural Flavonoids

    1 of 15 1 Study on Structure Activity Relationship of Natural 2 Flavonoids against Thrombin by Molecular Docking 3 Virtual Screening combined with Activity Evaluation 4 in vitro 5 Xiaoyan Wang1, 2 # , Zhen Yang3, 4 #, Feifei Su3, 4, Jin Li1, Evans Owusu Boadi 1, 2 , Yan-xu Chang1, 2*, 6 Hui Wang3, 4* 7 1 Tianjin State Key Laboratory of Modern Chinese Medicine, Tianjin University of Traditional Chinese 8 Medicine, Tianjin, 300193, China; 9 2 Tianjin Key Laboratory of Phytochemistry and Pharmaceutical Analysis, Tianjin University of Traditional 10 Chinese Medicine, Tianjin, 300193, China; 11 3 Tianjin Key Laboratory of Chinese medicine Pharmacology, Tianjin University of Traditional Chinese 12 Medicine, Tianjin, 300193, China 13 4 College of Chinese Materia Medica, Tianjin University of Traditional Chinese Medicine, Tianjin, 300193, 14 China 15 16 * Corresponding author: [email protected] (H.W.); [email protected] (Y.C) 17 Tel. /FAX: +86-22-59596163(S.F. &Y.C.) 18 # These authors contributed equally to this work. 19 20 21 22 Table S1 the docking score of 103 Compounds (In descending order of “-CDOCKER_energy”) 23 Figure S1 the Molecular structures of 42 flavonoids 24 25 26 27 28 Table S1 the docking score of 103 Compounds (In descending order of “-CDOCKER_energy”) 29 - -CDOCKER_ CDOCKER_IN energy TERACTION_ No. CAS compound (kcal/mol) energy (kcal/mol) 1 1257-08-5 (-)-Epicatechin gallate 52.0751 54.6293 2 83104-87-4 (-)-EGCG-3''-O-Me 51.2391 50.5546 3 20315-25-7 Proanthocyanidin B1 42.3509 55.9285 4 27200-12-0 Dihydromyricetin 40.3383
  • Flavonoids: Structure–Function and Mechanisms of Action and Opportunities for Drug Development

    Flavonoids: Structure–Function and Mechanisms of Action and Opportunities for Drug Development

    Toxicological Research Toxicol Res. eISSN 2234-2753 https://doi.org/10.1007/s43188-020-00080-z pISSN 1976-8257 INVITED REVIEW Flavonoids: structure–function and mechanisms of action and opportunities for drug development Stephen Safe1 · Arul Jayaraman2 · Robert S. Chapkin3 · Marcell Howard1 · Kumaravel Mohankumar1 · Rupesh Shrestha4 Received: 10 November 2020 / Accepted: 4 December 2020 © Korean Society of Toxicology 2021 Abstract Flavonoids are polyphenolic phytochemicals produced in fruits, nuts and vegetables and dietary consumption of these structurally diverse compounds is associated with multiple health benefts including increased lifespan, decreased cardio- vascular problems and low rates of metabolic diseases. Preclinical studies with individual favonoids demonstrate that these compounds exhibit anti-infammatory and anticancer activities and they enhance the immune system. Their efectiveness in both chemoprevention and chemotherapy is associated with their targeting of multiple genes/pathways including nuclear receptors, the aryl hydrocarbon receptor (AhR), kinases, receptor tyrosine kinases and G protein-coupled receptors. However, despite the remarkable preclinical activities of favonoids, their clinical applications have been limited and this is due, in part, to problems in drug delivery and poor bioavailability and these problems are being addressed. Further improvements that will expand clinical applications of favonoids include mechanism-based precision medicine approaches which will identify critical mechanisms of action